Cargando…
Long-Term Effect of Febuxostat on Endothelial Function in Patients With Asymptomatic Hyperuricemia: A Sub-Analysis of the PRIZE Study
BACKGROUND: Xanthine oxidase is involved in the production of uric acid and the generation of superoxide anion. We evaluated the long-term effect of febuxostat, a non-purine selective xanthine oxidase inhibitor, on endothelial function in patients with asymptomatic hyperuricemia. METHODS: In the PRI...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095910/ https://www.ncbi.nlm.nih.gov/pubmed/35571205 http://dx.doi.org/10.3389/fcvm.2022.882821 |
_version_ | 1784705856089096192 |
---|---|
author | Maruhashi, Tatsuya Higashi, Yukihito Yoshida, Hisako Tanaka, Atsushi Eguchi, Kazuo Tomiyama, Hirofumi Kario, Kazuomi Kato, Toru Oda, Nozomu Tahara, Nobuhiro Oguri, Mitsutoshi Watada, Hirotaka Node, Koichi |
author_facet | Maruhashi, Tatsuya Higashi, Yukihito Yoshida, Hisako Tanaka, Atsushi Eguchi, Kazuo Tomiyama, Hirofumi Kario, Kazuomi Kato, Toru Oda, Nozomu Tahara, Nobuhiro Oguri, Mitsutoshi Watada, Hirotaka Node, Koichi |
author_sort | Maruhashi, Tatsuya |
collection | PubMed |
description | BACKGROUND: Xanthine oxidase is involved in the production of uric acid and the generation of superoxide anion. We evaluated the long-term effect of febuxostat, a non-purine selective xanthine oxidase inhibitor, on endothelial function in patients with asymptomatic hyperuricemia. METHODS: In the PRIZE study, patients with hyperuricemia were randomly assigned to either add-on febuxostat treatment (febuxostat group) or non-pharmacologic hyperuricemia treatment (control group). Among the 514 participants, endothelial function was assessed in 41 patients in the febuxostat group and 38 patients in the control group by flow-mediated vasodilation (FMD) of the brachial artery at the beginning of the study and after 12 and/or 24 months of treatment (63 men; median age, 68.0 years). RESULTS: The least squares mean concentration of serum uric acid was significantly lower in the febuxostat group than in the control group at 6 months (mean between-group difference [febuxostat group - control group], −2.09 mg/dL [95% confidence interval (CI), −2.520 to −1.659]; P < 0.001), 12 months (mean between-group difference, −2.28 mg/dL [95% CI, −2.709 to −1.842]; P < 0.001), and 24 months (mean between-group difference, −2.61 mg/dL [95% CI, −3.059 to −2.169]; P < 0.001). No significant differences were found between groups in the least squares mean estimated percentage change in FMD at 12 months (mean between-group difference, −0.56% [95% CI, −1.670 to 0.548]; P = 0.319) and at 24 months (mean between-group difference, −0.60% [95% CI, −1.886 to 0.685]; P = 0.357). CONCLUSION: Febuxostat treatment did not alter endothelial function assessed by FMD during a 2-year study period in patients with asymptomatic hyperuricemia. |
format | Online Article Text |
id | pubmed-9095910 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90959102022-05-13 Long-Term Effect of Febuxostat on Endothelial Function in Patients With Asymptomatic Hyperuricemia: A Sub-Analysis of the PRIZE Study Maruhashi, Tatsuya Higashi, Yukihito Yoshida, Hisako Tanaka, Atsushi Eguchi, Kazuo Tomiyama, Hirofumi Kario, Kazuomi Kato, Toru Oda, Nozomu Tahara, Nobuhiro Oguri, Mitsutoshi Watada, Hirotaka Node, Koichi Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: Xanthine oxidase is involved in the production of uric acid and the generation of superoxide anion. We evaluated the long-term effect of febuxostat, a non-purine selective xanthine oxidase inhibitor, on endothelial function in patients with asymptomatic hyperuricemia. METHODS: In the PRIZE study, patients with hyperuricemia were randomly assigned to either add-on febuxostat treatment (febuxostat group) or non-pharmacologic hyperuricemia treatment (control group). Among the 514 participants, endothelial function was assessed in 41 patients in the febuxostat group and 38 patients in the control group by flow-mediated vasodilation (FMD) of the brachial artery at the beginning of the study and after 12 and/or 24 months of treatment (63 men; median age, 68.0 years). RESULTS: The least squares mean concentration of serum uric acid was significantly lower in the febuxostat group than in the control group at 6 months (mean between-group difference [febuxostat group - control group], −2.09 mg/dL [95% confidence interval (CI), −2.520 to −1.659]; P < 0.001), 12 months (mean between-group difference, −2.28 mg/dL [95% CI, −2.709 to −1.842]; P < 0.001), and 24 months (mean between-group difference, −2.61 mg/dL [95% CI, −3.059 to −2.169]; P < 0.001). No significant differences were found between groups in the least squares mean estimated percentage change in FMD at 12 months (mean between-group difference, −0.56% [95% CI, −1.670 to 0.548]; P = 0.319) and at 24 months (mean between-group difference, −0.60% [95% CI, −1.886 to 0.685]; P = 0.357). CONCLUSION: Febuxostat treatment did not alter endothelial function assessed by FMD during a 2-year study period in patients with asymptomatic hyperuricemia. Frontiers Media S.A. 2022-04-28 /pmc/articles/PMC9095910/ /pubmed/35571205 http://dx.doi.org/10.3389/fcvm.2022.882821 Text en Copyright © 2022 Maruhashi, Higashi, Yoshida, Tanaka, Eguchi, Tomiyama, Kario, Kato, Oda, Tahara, Oguri, Watada and Node. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Maruhashi, Tatsuya Higashi, Yukihito Yoshida, Hisako Tanaka, Atsushi Eguchi, Kazuo Tomiyama, Hirofumi Kario, Kazuomi Kato, Toru Oda, Nozomu Tahara, Nobuhiro Oguri, Mitsutoshi Watada, Hirotaka Node, Koichi Long-Term Effect of Febuxostat on Endothelial Function in Patients With Asymptomatic Hyperuricemia: A Sub-Analysis of the PRIZE Study |
title | Long-Term Effect of Febuxostat on Endothelial Function in Patients With Asymptomatic Hyperuricemia: A Sub-Analysis of the PRIZE Study |
title_full | Long-Term Effect of Febuxostat on Endothelial Function in Patients With Asymptomatic Hyperuricemia: A Sub-Analysis of the PRIZE Study |
title_fullStr | Long-Term Effect of Febuxostat on Endothelial Function in Patients With Asymptomatic Hyperuricemia: A Sub-Analysis of the PRIZE Study |
title_full_unstemmed | Long-Term Effect of Febuxostat on Endothelial Function in Patients With Asymptomatic Hyperuricemia: A Sub-Analysis of the PRIZE Study |
title_short | Long-Term Effect of Febuxostat on Endothelial Function in Patients With Asymptomatic Hyperuricemia: A Sub-Analysis of the PRIZE Study |
title_sort | long-term effect of febuxostat on endothelial function in patients with asymptomatic hyperuricemia: a sub-analysis of the prize study |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095910/ https://www.ncbi.nlm.nih.gov/pubmed/35571205 http://dx.doi.org/10.3389/fcvm.2022.882821 |
work_keys_str_mv | AT maruhashitatsuya longtermeffectoffebuxostatonendothelialfunctioninpatientswithasymptomatichyperuricemiaasubanalysisoftheprizestudy AT higashiyukihito longtermeffectoffebuxostatonendothelialfunctioninpatientswithasymptomatichyperuricemiaasubanalysisoftheprizestudy AT yoshidahisako longtermeffectoffebuxostatonendothelialfunctioninpatientswithasymptomatichyperuricemiaasubanalysisoftheprizestudy AT tanakaatsushi longtermeffectoffebuxostatonendothelialfunctioninpatientswithasymptomatichyperuricemiaasubanalysisoftheprizestudy AT eguchikazuo longtermeffectoffebuxostatonendothelialfunctioninpatientswithasymptomatichyperuricemiaasubanalysisoftheprizestudy AT tomiyamahirofumi longtermeffectoffebuxostatonendothelialfunctioninpatientswithasymptomatichyperuricemiaasubanalysisoftheprizestudy AT kariokazuomi longtermeffectoffebuxostatonendothelialfunctioninpatientswithasymptomatichyperuricemiaasubanalysisoftheprizestudy AT katotoru longtermeffectoffebuxostatonendothelialfunctioninpatientswithasymptomatichyperuricemiaasubanalysisoftheprizestudy AT odanozomu longtermeffectoffebuxostatonendothelialfunctioninpatientswithasymptomatichyperuricemiaasubanalysisoftheprizestudy AT taharanobuhiro longtermeffectoffebuxostatonendothelialfunctioninpatientswithasymptomatichyperuricemiaasubanalysisoftheprizestudy AT ogurimitsutoshi longtermeffectoffebuxostatonendothelialfunctioninpatientswithasymptomatichyperuricemiaasubanalysisoftheprizestudy AT watadahirotaka longtermeffectoffebuxostatonendothelialfunctioninpatientswithasymptomatichyperuricemiaasubanalysisoftheprizestudy AT nodekoichi longtermeffectoffebuxostatonendothelialfunctioninpatientswithasymptomatichyperuricemiaasubanalysisoftheprizestudy |